An immunodominant HLA-A*1101-restricted CD8+ T-cell response targeting hepatitis B surface antigen in chronic hepatitis B patients

Hepatitis B virus (HBV) infection is a worldwide public health problem. HBV-specific CD8 + CTLs are vital for viral clearance. Identification of immunodominant CTL epitopes from HBV-associated antigens is necessary for therapeutic vaccine development. We showed that the HLA-A*1101 allele is one of the most common alleles in both healthy individuals and chronic hepatitis B (CHB) patients in the Chongqing area, China. However, less than 10 % of epitopes of HBV-associated antigens have been identified in an HLA-A*1101 context. Here, we describe an immunodominant CD8 + T-cell response targeting a hepatitis B surface antigen determinant (HBs 295–304 ) restricted by HLA-A*1101 in both healthy individuals and CHB patients. Moreover, HBs 295–304 is more immunogenic for CTL induction than a known naturally HLA-A*1101-processed epitope from hepatitis B core antigen (HBc 88–96 ). Therefore, the newly identified epitope, HBs 295–304 , will benefit the development of immunotherapeutic approaches for HBV infection.